Actualités 49890.html
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
Thu, 26 Sep 2024 02:00:00 GMT
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new ...
Form 8.3 - ANGLOGOLD ASHANTI PLC
Mon, 16 Sep 2024 05:29:00 GMT
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b ...